Ocugen, Inc. Common Stock
OCGN Real Time Price USDRecent trades of OCGN by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by OCGN's directors and management
Government lobbying spending instances
-
$30,000 Oct 19, 2024 Issue: Health Issues
-
$60,000 Jul 22, 2024 Issue: Health Issues
-
$60,000 Apr 22, 2024 Issue: Health Issues
-
$30,000 Oct 20, 2023 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations
-
$60,000 Oct 19, 2023 Issue: Health Issues
-
$30,000 Jul 20, 2023 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations
-
$30,000 Jul 19, 2023 Issue: Health Issues
-
$20,000 Apr 20, 2023 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations
-
$30,000 Apr 18, 2023 Issue: Health Issues
-
$105,000 Feb 23, 2023 Issue: Health Issues
-
$10,000 Jan 20, 2023 Issue: Health Issues
-
$105,000 Nov 16, 2022 Issue: Health Issues
-
$105,000 Aug 08, 2022 Issue: Health Issues
-
$20,000 Jul 20, 2022 Issue: Pharmacy
-
$105,000 Jun 09, 2022 Issue: Health Issues
-
$130,000 Apr 20, 2022 Issue: Pharmacy
-
$60,000 Jan 20, 2022 Issue: Health Issues
-
$130,000 Jan 20, 2022 Issue: Pharmacy
-
$60,000 Oct 21, 2021 Issue: Health Issues
-
$30,000 Oct 20, 2021 Issue: Pharmacy
-
$60,000 Jul 19, 2021 Issue: Health Issues
-
$60,000 Jul 19, 2021 Issue: Health Issues
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Method for use of a double-structured tissue implant for treatment of tissue May. 16, 2023
-
Patent Title: Cell and tissue culture container Jan. 17, 2023
-
Patent Title: Preservative free ocular compositions and methods for using the same for treating dry eye disease and other eye disorders Aug. 25, 2020
-
Patent Title: Ophthalmic compositions and methods of use Feb. 11, 2020
-
Patent Title: Methods and compositions for treating dry eye disease and other eye disorders Jan. 30, 2018
-
Patent Title: Methods and compositions for treating dry eye disease and other eye disorders Mar. 21, 2017
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of OCGN in WallStreetBets Daily Discussion
Recent insights relating to OCGN
Recent picks made for OCGN stock on CNBC
ETFs with the largest estimated holdings in OCGN
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view OCGN Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.